Cure of human immunodeficiency virus/acquired immune deficiency syndrome: promising future prospects at horizon

Sagar Shashikant Panchal, Prasad R. Pandit, Abhishek M. Phatak, Madhura S. Naik, Komal M. Lohi


Acquired immune deficiency syndrome (AIDS) is a disease caused by human
immunodeficiency virus and characterized by profound immunosuppression that
leads to opportunistic infections, secondary neoplasms, and neurologic complications.
AIDS is among the leading causes of death worldwide. Current therapeutic options
are directed only toward management of AIDS, but not toward its prevention or cure.
In addition, it also possesses numerous problems like drug resistance, drug toxicity,
drug interactions, non-adherence to therapy, life-long and expensive treatment, etc.
Recent years in drug development have shown promising prospects for prevention/
treatment/cure of AIDS like histone deacetylase inhibitors, Vpu ion channel inhibitors,
viral decay acceleration, maturation inhibitors, tat antagonists, gene/stem cell therapy,
and antiretroviral vaccines.


Antiretroviral therapy, Belinostat, Bevirimat, Valproic acid, National Acquired Immune Deficiency Syndrome Control Organization, Targeted therapies

Full Text:



World Health Organization. HIV Data; 2014. Available at Accessed 22 April 2015.

National AIDS Control Organization. State fact sheets; 2013. Available at Accessed 22 April 2015.

Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347(6):385-94.

De La Torre-Lima J, Aguilar A, Santos J, Jiménez-Oñate F, Marcos M, Núñez V, et al. Durability of the first antiretroviral treatment regimen and reasons for change in patients with HIV infection. HIV Clin Trials. 2014;15(1):27-35.

AIDS info. Adherence to Antiretroviral Therapy. Available at Accessed 23 April 2015.

Dooley KE, Flexner C, Andrade AS. Drug interactions involving combination antiretroviral therapy and other anti-infective agents: repercussions for resource-limited countries. J Infect Dis. 2008;198(7):948-61.

Grant R, Rachel S, Chu Y, Stephen A. Autophagy induction by histone deacetylase inhibitors inhibits HIV Type1. J Biol Chem. 2014;290(8):1-27.

Rasmussen A, Tolstrup M, Brinkmann C, Olesen R, Erikstrup C, Solomon A, et al. Panobinostat: a histone deacetylase inhibitor for latent –virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV. 2014;1(1):13-21.

Ewart G, Sutherland T, Gage P, Cox G. The VPU protein of human immunodeficiency virus Type 1 forms cation-selective ion channels. J Virol. 1996;70(10):7108-15.

Ewart GD, Mills K, Cox GB, Gage PW. Amiloride derivatives block ion channel activity and enhancement of virus-like particle budding caused by HIV-1 protein Vpu. Eur Biophys J 2002;31(1):26-35.

Wilkinson JB. Inhibiting Vpu Function with the Novel Compound BIT225, Results in Inhibition of HIV-1 Release from Human Macrophage Reservoirs. Available at Accessed 24 April 2015.

Zhang J, Ge W, Zhan P, De Clercq E, Liu X. Retroviral restriction factors TRIM5α: therapeutic strategy to inhibit HIV1 replication. Curr Med Chem 2011;18(17):264954.

Retrovirology. Nathalie A. Revisiting HIV-1 Uncoating. Available at Accessed 24 April 2015.

Stremlau M, Perron M, Lee M. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5 restriction factor. PNAS. Available at Accessed 25 April 2015.

Martin DE, Salzwedel K, Allaway GP. Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection. Antivir Chem Chemother. 2008;19(3):107-13.

Salzwedel K, Martin DE, Sakalian M. Maturation inhibitors: a new therapeutic class targets the virus structure. AIDS Rev. 2007;9(3):162-72.

Martin DE, Galbraith H, Schettler J, Ellis C, Doto J. Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study. Clin Ther. 2008;30(10):1794-805.

Cupelli LA, Hsu MC. The human immunodeficiency virus type 1 Tat antagonist, Ro 5-3335, predominantly inhibits transcription initiation from the viral promoter. J Virol. 1995;69(4):2640-3.

Choudhury I, Wang J, Stein S, Rabson A, Leibowitz MJ. Translational effects of peptide antagonists of Tat protein of human immunodeficiency virus type 1. J Gen Virol. 1999;80:777-82.

Rusnati M, Presta M. HIV-1 Tat protein: a target for the development of anti-AIDS therapies. Drugs Future. 2002;7(5):481-93.

Mullins J, Heath L, Hughes J. Mutations based on viral decay acceleration in the HIV1 genomes of a clinical population treated with the mutagenic nucleoside KP1461. Retrovirology. Available at Accessed 24 April 2014.

Ribosome inactivating proteins from plants inhibiting viruses. Available at 2011. Accessed 24 April 2015.

Wang YY, Ouyang DY, Huang H, Chan H, Tam SC, Zheng YT. Enhanced apoptotic action of trichosanthin in HIV-1 infected cells. Biochem Biophys Res Commun. 2005;331(4):1075-80.

Durai S, Mani M, Kandavelou K, Wu J, Porteus MH, Chandrasegaran S, et al. Zinc finger nucleases: customdesigned molecular scissors for genome engineering of plant and mammalian cells. Nucleic Acids Res. 2005;33(18):5978-90.

Yuan J, Wang J, Crain K, Fearns C, Kim KA, Hua KL, et al. Zinc-finger nuclease editing of human cxcr4 promotes HIV-1 CD4(+) T cell resistance and enrichment. Mol Ther. 2012;20(4):849-59.

Durand C, Siliciano R. Dual zinc-finger nucleases block HIV infection. Blood J. 2014;123(1):2-3.